◆ 会议时间：2023年3月20日至22日
◆ 会议地点：瑞士 卢加诺

◆ 会议简介：

2023年ESMO肉瘤和罕见癌症大会将于2023年3月20日至22日在瑞士卢加诺举行，会议由欧洲肿瘤内科学会(ESMO)主办。本次高度专业化的会议将整合前ESMO肉瘤和GIST研讨会以及ESO-ESMO-RCE罕见成人实体肿瘤临床更新的内容，汇集研究这些肿瘤类型的最杰出的医学人才。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

ESMO Sarcoma & Rare Cancers Congress 2023
Date: 20-22 March 2023
Venue: Lugano, Switzerland

This highly specialised meeting will integrate contents from both the former ESMO Sarcoma GIST & Symposium and the ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, bringing together the most brilliant medical minds working on these tumour types.

The ESMO Sarcoma & Rare Cancers Congress will constitute a unique occasion for the international rare cancers community to network and collaborate, featuring discussions with key opinion leaders in these sub-entities.

The congress will focus on the heterogeneous cohort of rare histologies across organ sites, and on their common themes: from diagnosis and pathology, to multidisciplinary expert management, from targeted therapies and precision medicine, to research, methodological challenges and policy.

We look forward to welcoming you next spring to Lugano for three days of debates on the advancements in the treatment of rare cancers.

摘要征文投稿：

Abstract submission deadlines

点此提交摘要>>>Submit Abstract>>>

ESMO Sarcoma and Rare Cancers 2023 Abstract Regulations

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters by end-January 2023.

Submission categories

• Central Nervous System (CNS)
• Digestive cancers
• Genitourinary cancers
• Gynaecological cancers
• Head and neck cancers
• Neuroendocrine and Endocrine cancers
• Public Policy and Patient Advocacy
• Research methodology
• Sarcoma
• Skin cancers and Melanomas
• Thoracic cancers
• Miscellaneous

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Sarcoma and Rare Cancers Congress 2023.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of Wednesday, 11 January 2023.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will be accepted for Poster outcome only.
• Encore TiP abstracts will not be accepted.

Publication schedule of accepted abstracts

Details regarding the publication of accepted abstracts will be available on this page in due time.

Embargo policy

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

Presentation of accepted abstracts

The ESMO Sarcoma and Rare Cancers 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work during Poster display session.

All accepted abstracts will be published online in the ESMO Sarcoma and Rare Cancers Congress 2023 Abstract Book, a supplement to ESMO Open.

注册费：

In-person participation includes:

• Participation in the scientific and educational live sessions with the possibility to interact with the expert panel
• Onsite networking opportunity with faculty and peers
• Entry to the Poster area
• Interaction with the industry partners in the trade exhibition
• Participation in the Industry Satellite Symposia
• Post-event resources
• Coffee breaks and lunches

Registration fees and deadlines

Individual registration will remain open for the duration of the congress. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines. 

*Applicable to ESMO members from developing countries only. Developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees. 

**ESMO Members must be under 40 and in training to qualify for this fee

Webcasts

The Congress webcasts will be available for all delegates and will include all the sessions of the official programme where speaker permission is granted. The content will be available to OncologyPRO and will be accessible to all registered delegates, non-Members for 24 months. ESMO Members who do not register for the Congress will have access to the resources 3 months after the end of the Congress.